---
title: "PMGC Surges 29% on Subsidiary FACS Research Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292328562.md"
description: "PMGC jumps 29% to $1.369 as NorthStrive plans independent flow cytometry study for EL-22 antigen quantification."
datetime: "2026-07-10T13:41:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292328562.md)
  - [en](https://longbridge.com/en/news/292328562.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292328562.md)
---

# PMGC Surges 29% on Subsidiary FACS Research Plan

PMGC(ELAB.US) 盘中涨超**29%**，现报**1.369 美元**。

消息面上，PMGC 旗下子公司 NorthStrive Biosciences 计划开展独立流式细胞术研究，以量化工程化 Lactobacillus casei 的 EL-22 抗原表达，确保制造可比性并支持监管准备。

### Related Stocks

- [ELAB.US](https://longbridge.com/en/quote/ELAB.US.md)

## Related News & Research

- [PMGC unit A&B Aerospace signs long-term supply agreement with PAD Group](https://longbridge.com/en/news/294060161.md)
- [PMGC unit NorthStrive signs exclusive FSU license to develop multi-domain drone payload technology](https://longbridge.com/en/news/292481384.md)
- [PMGC unit NorthStrive to launch independent FACS study to quantify EL-22 antigen expression](https://longbridge.com/en/news/292316283.md)
- [PMGC Holdings Subsidiary Secures Exclusive License for Aerospace and Defense Patent 12,291,334](https://longbridge.com/en/news/291979789.md)
- [PMGC unit NorthStrive Biosciences files two US patent applications for muscle preservation in GLP-1 weight loss market](https://longbridge.com/en/news/290190535.md)